A phase 3 trial to investigate JHL1922 in cystic fibrosis patients.
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Dornase alfa (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 27 Dec 2018 According to a JHL Biotech media release, this trial is expected to begin in 2019.
- 05 Feb 2018 New trial record
- 01 Feb 2018 According to a JHL Biotech media release, company plans to initiate this study in 2018.